ORKA
Oruka Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +14.3% ·
share flow -30.0% ·
net new positions +12.5%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +25 | 38.88M | $3.70B | +30 | −5 |
| Q1 2026 | 76 | +12 | 25.47M | $1.25B | +17 | −5 |
| Q4 2025 | 63 | +1 | 24.86M | $753.58M | +1 | — |
| Q3 2025 | 15 | +1 | 17.63M | $338.97M | +3 | −2 |
| Q2 2025 | 11 | 0 | 11.37M | $127.46M | +1 | −1 |
| Q1 2025 | 8 | +1 | 1.39M | $14.29M | +2 | −1 |
| Q4 2024 | 7 | +1 | 2.25M | $43.63M | +1 | — |
| Q3 2024 | 5 | +5 | 1.06M | $25.93M | +5 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 411.60K | -69.0% | $4.22M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 352.58K | +3.0% | $3.62M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Point72 Asset Management ✦ | 342.40K | -5.1% | $3.51M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 87.50K | -8.0% | $897,761 | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 5 | State Street Global Advisors ✦ (passive) | 86.68K | +246.4% | $889,347 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 54.13K | +78.6% | $555,333 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 35.80K | New | $367,308 | 0.0% | New | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 21.83K | New | $223,986 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $367,308 | 0.0% |
| Two Sigma Investments | $223,986 | 0.0% |
Exited
| Adage Capital Partners | $1.34M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 183 holders, 52.32M shares, $2.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 601 sh · $56,760
Officer · 3.83K sh · $357,592
Officer · 2.90K sh · $267,870
Officer · 533 sh · $51,035
Officer · 2.67K sh · $254,196
Officer · 560 sh · $53,598
Officer · 1.04K sh · $99,443
Officer · 906 sh · $86,713
Officer, Director · 2.45K sh · $234,681
Officer · 947 sh · $90,637
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
19.5% of class · View original SEC filing ↗